GET DAILY SIGNALSBeOne Medicines (ONC) Reports +33% Revenue Growth in Q3 2026 on Strong Oncology Demand
Key Takeaways
- Total revenue reached $1.89 billion in the third quarter of 2026, up 33% year over year, driven by strong demand across the oncology portfolio.
- GAAP diluted earnings per American Depositary Share (ADS) climbed to $3.28 from $1.09 a year earlier, while adjusted (non-GAAP) diluted earnings per ADS rose to $4.59 from $2.65.
- BRUKINSA (zanubrutinib) global sales grew 34% to roughly $1.4 billion, with U.S. sales surpassing $1 billion in a single quarter for the first time.
- Net income increased to about $384.7 million, and free cash flow rose 34% to $474 million, underscoring improving profitability.
- Management raised its full-year 2026 revenue guidance following the better-than-expected quarter.
Why the Quarter Matters
BeOne Medicines, formerly BeiGene, has positioned itself as a global oncology player, and its third-quarter 2026 results provide a useful check on whether that growth can continue while margins improve. The company has posted consistent double-digit revenue increases and beaten estimates over the past year, supported by rising demand for BRUKINSA and TEVIMBRA. This report is notable because it reflects the U.S. launch of expanded BRUKINSA indications and early traction for newer products. From what I see, the numbers give investors a clearer picture of pricing power, market share gains, margin trends, and cash generation in a competitive cancer-drug space.
Quarterly Results in Detail
BeOne Medicines reported third-quarter 2026 total revenue of $1,889.8 million, up 33% from $1,412.3 million in the prior-year period and ahead of analyst expectations of roughly $1.75 billion. GAAP diluted earnings per ADS reached $3.28 versus $1.09 a year ago, while adjusted diluted earnings per ADS climbed to $4.59 from $2.65. Net income rose to $384.7 million from $124.8 million. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Growth was broad-based across the portfolio. BRUKINSA generated approximately $1.4 billion in global sales, up 34% year over year, with U.S. revenue exceeding $1 billion for the first time on 36% growth. TEVIMBRA contributed roughly $243 million, up 28%. The Amgen in-license portfolio added about $167 million, up 26%. Gross margin stood at approximately 88%, and free cash flow increased 34% to $474 million, pointing to stronger operating leverage.
Market Reaction
Shares of BeOne Medicines traded higher after the release, reflecting investor enthusiasm for the revenue beat, the first $1 billion U.S. quarter for BRUKINSA, and the raised full-year outlook. Sentiment ahead of the report had been constructive given multiple prior beats and steady momentum in core franchises. The positive response indicates investors see the growth as durable and increasingly profitable, though attention remains on competitive pressures and potential biosimilar or pricing dynamics for certain in-licensed products.
Forward Outlook and Factors to Watch
Looking ahead, several themes stand out. The trajectory of BRUKINSA remains the main growth engine, with U.S. expansion, new patient starts, and treatment duration all supporting demand. Management noted an approximate $50 million benefit from order timing, so the fourth quarter will help clarify the underlying run rate. Newer launches and pipeline milestones also matter. TEVIMBRA continues to gain share in China and new markets, while the U.S. launch of BEQALZI and the HERIZON regimen in first-line HER2-positive gastric cancer are early but closely watched. Several late-stage and pivotal trials, including programs in chronic lymphocytic leukemia and hepatocellular carcinoma, could deliver key data through 2027.
Margin and cash-flow trends deserve monitoring as well. Expanding operating income and rising free cash flow signal improving scalability, yet continued R&D and commercial investment will shape profitability. Updates to full-year guidance and the effects of foreign exchange or competitive pressures on in-licensed products remain worth watching beyond 2026.
My Experience with Tickeron Tools
When preparing this review, I used Tickeron’s AI Screener to quickly filter oncology names and compare technical and fundamental signals. The tool helped surface relevant peers and recent patterns without manual effort, which is useful when evaluating a single name like ONC alongside broader sector trends. It integrates well into a regular research routine for building or refining watchlists.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for ONC turns negative, indicating new downward trend
ONC saw its Momentum Indicator move below the 0 level on November 02, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 76 similar instances where the indicator turned negative. In 59 of the 76 cases, the stock moved further down in the following days. The odds of a decline are at 78%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for ONC moved out of overbought territory on October 22, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 similar instances where the indicator moved out of overbought territory. In 29 of the 38 cases, the stock moved lower in the following days. This puts the odds of a move lower at 76%.
The Moving Average Convergence Divergence Histogram (MACD) for ONC turned negative on October 29, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 38 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 78%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ONC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 46 of 64 cases where ONC's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 72%.
ONC moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ONC crossed bullishly above the 50-day moving average on October 20, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 21 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 62%.
Following a +4.40% 3-day Advance, the price is estimated to grow further. Considering data from situations where ONC advanced for three days, in 222 of 301 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
ONC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 187 of 260 cases where ONC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 72%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating steady price growth. ONC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 58 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.260) is normal, around the industry mean (2.904). P/E Ratio (64.578) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (0.776) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (6.553) is also within normal values, averaging (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 94 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ONC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of biopharmaceutical products
Industry Biotechnology
Advertisement